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Abstract 
Background: Laser therapy has been the gold standard treatment for retinopathy of prema-
turity (ROP), while intravitreal bevacizumab (IVB) is reported to be of significant benefit for 
zone I ROP. A problem with laser therapy is that it is difficult to administer in ROP patients 
with severely dilated tunica vasculosa lentis and poor mydriasis. However, although IVB treat-
ment has been performed in such severe ROP cases, only 1 report has discussed its useful-
ness. Case 1: A male infant was born with a birth weight of 382 g at 23 weeks’ gestation. As 
visualization was poor and laser therapy could not be performed due to dilated tunica vascu-
losa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) was administered to both eyes. Fol-
lowing treatment, the ROP gradually improved, with regression of the dilated tunica vascu-
losa lentis and improvement of the mydriasis in both eyes. Case 2: A male infant was born 
with a birth weight of 698 g at 25 weeks’ gestation. As laser therapy could not be performed 
due to severely dilated tunica vasculosa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) 
was administered to both eyes. Following treatment, the ROP gradually improved, with re-
gression of the dilated tunica vasculosa lentis and improvement of the mydriasis in both 
 Case Rep Ophthalmol 2017;8:173–179 
DOI: 10.1159/000461575 © 2017 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/cop 
Higashiyama et al.: Usefulness of Intravitreal Bevacizumab for Retinopathy of Prematurity 
with Severely Dilated Tunica Vasculosa Lentis and Poor Mydriasis 
 
 
 
 
174 
eyes. Conclusions: IVB is potentially more useful than laser therapy for the treatment of se-
vere ROP with dilated tunica vasculosa lentis and poor mydriasis. 
 © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Retinopathy of prematurity (ROP) is a disorder of retinal vascular development and a 
major cause of childhood blindness [1]. Low birth weight and prematurity are strongly asso-
ciated with the risk of ROP [2]. In cases of severe ROP, dilated tunica vasculosa lentis and 
poor mydriasis are evident, along with intravitreal angiogenesis [3–6]. Severe ROP, such as 
type 1 ROP defined by the Early Treatment for Retinopathy of Prematurity study, should be 
treated as soon as possible because it can rapidly progress to fibrovascular retinal detach-
ment [7]. 
The current treatments for ROP are laser therapy and intravitreal bevacizumab (IVB) 
[8–11]. Laser therapy has been the gold standard treatment for ROP, while IVB is reported to 
be of significant benefit for zone I stage 3+ (i.e., stage 3 with plus disease) ROP when com-
pared with laser therapy [8]. A problem with laser therapy is that it is difficult to administer 
in ROP patients with severely dilated tunica vasculosa lentis and poor mydriasis, because  
the treatment requires clear optic media and adequate mydriasis. However, IVB treatment 
can be used in such circumstances as it does not require clear optic media and adequate 
mydriasis. 
To the best of our knowledge, only 1 report has described the usefulness of IVB for the 
treatment of severe ROP in which laser therapy was not feasible [12]. In this study, we re-
port 2 cases in whom IVB was effective for the treatment of ROP with severely dilated tunica 
vasculosa lentis and poor mydriasis. 
Case Reports 
Case 1 
A male infant was born with a birth weight of 382 g at 23 weeks’ gestation. From birth, 
he received oxygen therapy for respiratory distress syndrome. The first ophthalmic exami-
nation was performed at 35.4 weeks because his general health had been poor. In the exam-
ination, type 1 ROP (zone I stage 3+) with dilated tunica vasculosa lentis and poor mydriasis 
was diagnosed in both eyes (Fig. 1a, b, Fig. 2a, b). As laser therapy could not be performed 
due to dilated tunica vasculosa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) was 
administered to both eyes on the day following the first examination. Following treatment, 
the ROP gradually improved, with regression of the dilated tunica vasculosa lentis and  
improvement of the mydriasis in both eyes (Fig. 1c, d, Fig. 2c, d). Fundus examination  
8 months after treatment revealed vascularization to the edge of the ora serrata, and a fur-
ther fundus examination 1 year after treatment revealed no recurrence of the ROP. 
Case 2 
A male infant was born in a hospital with a birth weight of 698 g at 25 weeks’ gestation. 
From birth, he received oxygen therapy for respiratory distress syndrome at the hospital. 
Ophthalmic examination revealed type 1 ROP (zone I stage 3+) with dilated tunica vasculosa 
lentis and poor mydriasis in both eyes. At 37.4 weeks of age, he was transferred to our hospi-
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tal for treatment with IVB because laser therapy could not be performed due to severely 
dilated tunica vasculosa lentis and poor mydriasis. We performed a fundus examination and 
confirmed the diagnosis of type 1 ROP (zone I stage 3+) with dilated tunica vasculosa lentis 
and poor mydriasis in both eyes (Fig. 3a, b). Treatment with IVB (0.625 mg/0.025 mL) was 
subsequently administered to both eyes immediately following the examination. Following 
treatment, the ROP gradually improved, with regression of the dilated tunica vasculosa lentis 
and improvement of the mydriasis in both eyes (Fig. 3c, d). Fundus examination 1 year after 
treatment revealed no recurrence of the ROP. 
Discussion 
We report 2 cases of ROP with severely dilated tunica vasculosa lentis and poor mydria-
sis who were both effectively treated with IVB. An advantage of IVB is that it can be per-
formed in cases of severe ROP with poor visualization due to dilated tunica vasculosa lentis 
and poor mydriasis, when laser therapy is not feasible. Law et al. [12] reported that admin-
istration of IVB prior to laser therapy or vitrectomy improved treatment outcomes for ROP 
with poor mydriasis, iris rubeosis, and vitreous hemorrhage. In our current report, IVB was 
found to be effective as a monotherapy for severe ROP for which laser therapy could not be 
performed. Therefore, IVB is potentially more useful than laser therapy for the treatment of 
severe ROP with dilated tunica vasculosa lentis and poor mydriasis. In addition, such ROP 
cases might improve with only monotherapy of IVB. 
IVB also offers other advantages for the treatment of ROP when compared with laser 
therapy. IVB can be used to treat ROP with dense vitreous hemorrhages and hazy media that 
make laser therapy difficult. The IVB procedure is also less invasive and takes less time than 
laser therapy. Finally, intravitreal injection is technically easier to perform than laser thera-
py, although there is a risk of complications, such as lens injury [8]. 
A previous study reported the efficacy of IVB for severe ROP. Mintz-Hittner et al. [8] re-
ported significantly lower recurrence percentages of ROP with IVB treatment of zone I stage 
3+ ROP patients compared with laser therapy. Our current report also showed improvement 
in 2 cases of zone I stage 3+ ROP, with no recurrence following IVB treatment. 
In conclusion, IVB has an advantage compared with laser therapy for ROP. IVB is poten-
tially more useful than laser therapy for cases of severe ROP with dilated tunica vasculosa 
lentis and poor mydriasis. 
Statement of Ethics 
This study was approved by the Institutional Review Board of Shiga University of Medi-
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Fig. 1. Photographs of the anterior segment in case 1. a, b The anterior segment of the right eye (a) and the 
left eye (b) before treatment. Dilated tunica vasculosa lentis and poor mydriasis were observed in both 
eyes. c, d The anterior segment of the right eye (c) and the left eye (d) 4 days after treatment. The dilated 
tunica vasculosa lentis had regressed and the mydriasis was improved in both eyes. 
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Fig. 2. Fundus photographs in case 1. a, b Fundus of the right eye (a) and the left eye (b) before treatment. 
Type 1 retinopathy of prematurity (ROP) with plus disease was observed in both eyes, although visualiza-
tion was poor due to dilated tunica vasculosa lentis and poor mydriasis. c, d The fundus of the right eye (c) 
and the left eye (d) 4 days after treatment. ROP was improved in both eyes although mild vitreous hemor-
rhage was observed after treatment. 
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Fig. 3. Photographs of the anterior segment in case 2. a, b The anterior segment of the right eye (a) and the 
left eye (b) before treatment. Dilated tunica vasculosa lentis and poor mydriasis were observed in both 
eyes. c, d The anterior segment of the right eye (c) and the left eye (d) 3 days after treatment. The dilated 
tunica vasculosa lentis had regressed and mydriasis was improved in both eyes. 
 
